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α2-Adrenoceptors lower central sympathetic output and peripheral catecholamine release,
and thus may prevent sympathetic hyperactivity and hypertension. α2AR also influence
vascular tension. These α2AR are malfunctioning in spontaneously hypertensive rats
(SHR). Here I tested if an interaction between α2AR subtypes and the angiotensin AT1
receptor (AT1R) precipitated these disorders. Blood pressure was monitored through
a femoral artery catheter and cardiac output by ascending aorta flow in anesthetized
rats. Catecholamine concentrations were determined in plasma collected at the end of
a 15-min tyramine-infusion. Tyramine stimulates norepinephrine release through the re-
uptake transporter, thus preventing re-uptake. Presynaptic control of vesicular release is
therefore reflected as differences in overflow to plasma. Previous experiments showed
surgical stress to activate some secretion of epinephrine, also subjected to α2AR-
auto-inhibition. Normotensive rats (WKY) and SHR were pre-treated with (1) vehicle
or α2AR-antagonist (L-659,066), followed by fadolmidine (α2C>B>A+ α1AR-agonist), ST-91
(α2non-A-selective agonist), or m-nitrobiphenyline (α2CAR-agonist+ α2A+B-antagonist), or (2)
AT1R-antagonist losartan, losartan+L-659,066, or losartan+ clonidine. In WKY, L-659,066
alone, L-659,066+ agonist or losartan+L-659,066 increased catecholamine overflow to
plasma after tyramine and eliminated the norepinephrine-induced rise in total peripheral
vascular resistance (TPR). In SHR, L-659,066+ fadolmidine/ST-91/m-nitrobiphenyline and
losartan+L-659,066 greatly increased, and losartan+ clonidine reduced, catecholamine
concentrations, and L-659,066+ST-91, losartan+L-659,066 and losartan+ clonidine elimi-
nated the tyramine-induced rise inTPR. Separately, these drugs had no effect in SHR. In con-
clusion, peripheral α2CAR-stimulation or AT1R-inhibition restored failing α2AAR-mediated
auto-inhibition of norepinephrine and epinephrine release and control of TPR in SHR.
Keywords: α2-adrenoceptors, angiotensinAT1 receptor, sympathetic nervous system, norepinephrine, epinephrine,
release-control, spontaneously hypertensive rats, total peripheral vascular resistance
INTRODUCTION
Sympathetic hyperactivity is a major force in initiating and sus-
taining spontaneous hypertension (Guyenet, 2006; Esler, 2011).
α2-adrenoceptors (AR) lower sympathetic output from the cen-
tral nervous system (CNS), and inhibit release of norepinephrine
from peripheral sympathetic nerves and catecholamines from the
adrenal medulla (Starke, 2001). Their activation is tonic, and they
hamper release even in the anesthetized rat without stimulation of
norepinephrine release (Berg et al., 2012). They therefore repre-
sent the last line of defense against sympathetic hyperactivity, and,
if not functioning, plasma norepinephrine levels and blood pres-
sure (BP) will increase, as demonstrated in genetically modified
mice (Makaritsis et al., 1999). In the spontaneously hyperten-
sive rat (SHR), deficiencies have been detected in both central
and peripheral α2AR-mediated inhibition of release (Remie et al.,
1992; Zugck et al., 2003). We have recently demonstrated that
during tyramine-stimulated norepinephrine release, α2AR failed
to lower norepinephrine and epinephrine release in SHR, and
also failed to control vascular tension (Berg and Jensen, 2013).
These malfunctions were not detected without activation of nor-
epinephrine release (Berg et al., 2012), indicating that they resulted
from the released catecholamine itself, or another agent released
by, or co-released with norepinephrine or epinephrine. Surpris-
ingly, these peripheral disorders were repaired by the non-selective
agonist clonidine, which reduced catecholamine release, and also,
through a central action, normalized the high resting BP, heart rate
(HR), and total peripheral vascular resistance (TPR) in SHR (Berg
et al., 2012).
The restoring effect of clonidine may result from its central
action or from an interaction between presynaptic receptors.α2AR
are divided into three subtypes, i.e., α2A, α2B, and α2C. The α2A-
and α2C-subtypes mediated the inhibition of central sympathetic
output, whereas all three subtypes may reduce norepinephrine
release from peripheral sympathetic nerves (Hein et al., 1999;
Trendelenburg et al., 2003b) and the adrenal medulla (Brede
et al., 2003; Moura et al., 2006). Inhibition of adrenal epinephrine
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release involved the α2C-subtype in the mouse (Brede et al., 2003;
Moura et al., 2006), but the α2A-subtype in rat and man (Lym-
peropoulos et al., 2007; Berg et al., 2012). It has been shown
that on-going α2AR-signaling markedly enhanced the stimulat-
ing effect of the angiotensin AT1 receptor (AT1R) – phospho-
lipase C – protein kinase C (PKC) pathway on norepinephrine
release in the rat vas deferens (Talaia et al., 2006). Similarly,
studies on tissues from genetically modified mice (Trendelenburg
et al., 2003a) demonstrated that the enhancing effect of release-
stimulating receptors, including the AT1R, depended on active
α2AR-signaling. However, the interaction involved the α2CAR-
subtype only (Figure 1). Since the renin angiotensin system plays
a significant role in hypertension pathology in SHR, I hypoth-
esized that the clonidine-dependent restoration of α2AR inhibi-
tion of release in SHR involved stimulation of the α2CAR, thus
counter-acting an excessive AT1R-signaling.
The angiotensin II responsible for a possible AT1R interfer-
ence in SHR is not likely to origin from the sympathetic nerves
themselves. Therefore, to have all components present, a role
of the AT1R in the α2AR malfunction in SHR should be tested
in vivo, which represents an experimental challenge. Due to
synaptic uptake of norepinephrine through the norepinephrine
re-uptake transporter (NET), presynaptic modulation of release
is not reflected as differences in overflow and the plasma nor-
epinephrine concentration (Berg et al., 2012). However, when
FIGURE 1 |The effect of presynaptic α2CAR andAT1R on norepinephrine
release. AT1R-Gq-signaling stimulates norepinephrine release by interfering
with the down-stream signaling of Gi (Cox et al., 2000). The AT1R/α2AR
interaction involved only the α2C- and not the α2A-subtype (Trendelenburg
et al., 2003a). The present results show that α2CAR-stimulation or
AT1R-inhibition was required for α2AAR to effectively moderate peripheral
norepinephrine release in SHR during tyramine-stimulated norepinephrine
release. This malfunction may be due to excessive AT1R-Gq-signaling in this
strain, and α2A-signaling was evidently not permitted as long as
AT1R-Gq-signaling interfered with the function of the α2CAR. Tyramine
stimulates reverse transport of norepinephrine through NET, and therefore
also prevents synaptic NET re-uptake, allowing presynaptic control of
release to be reflected as differences in overflow and the plasma
norepinephrine concentration.
NET-mediated re-uptake was blocked by desipramine, α2AR-
antagonists greatly increased the plasma concentration of norepi-
nephrine in the resting, anesthetized rat, in which norepinephrine
release was not stimulated. Overflow to plasma under resting
conditions is low, and inhibition of release by α2AR-agonist had
no or little effect on the plasma norepinephrine concentration
(Berg et al., 2012). In addition, the α2AR malfunction in SHR
was not observed unless norepinephrine release was activated.
Peripheral norepinephrine release can be stimulated by tyramine,
which activates reverse transport through NET. Most likely by
engaging NET in release, thus preventing re-uptake, presynap-
tic α2AR modulation altered tyramine-induced norepinephrine
overflow to plasma, similar to that after desipramine in not-
stimulated rats (Berg and Jensen, 2013). Restored α2AR control of
release after α2CAR-stimulation or AT1R-antagonist could there-
fore be tested by the ability of the non-selective α2AR-antagonist
L-659,066 to increase tyramine-induced norepinephrine overflow
to plasma.
Epinephrine released in the adrenals is not subjected to
re-uptake, and is not stimulated by tyramine. However, the
stress induced by the surgical procedure activated some secre-
tion of epinephrine, which was also subjected to α2AR-mediated
release-control (Berg et al., 2012; Berg and Jensen, 2013).
Due to the activation of norepinephrine release, tyramine in
addition induced a sympathetic cardiovascular response. This
response was not influenced by baroreceptor activation, demon-
strated by that baroreceptor control of HR was abolished by the
pentobarbital-anesthesia (Berg et al., 2012). Moreover, epineph-
rine secretion is not regulated by the baroreceptor reflex. Thus, by
recording BP and cardiac output (CO), the implications of altered
catecholamine release and a possible postsynaptic α2AR/AT1R
interaction in the control of TPR could be evaluated.
The results will show that the failing α2AR control of nor-
epinephrine and epinephrine release and modulation of the
norepinephrine-induced rise in TPR in SHR was restored by
stimulation of peripheral α2CAR or inhibition of the AT1R.
MATERIALS AND METHODS
EXPERIMENTAL PROCEDURE
All experiments were approved by the institutional review commit-
tee, and conducted in accordance with the Directive 2010/63/EU
of the European Parliament. About 12–14 weeks old, male nor-
motensive rats (Wistar Kyoto, WKY, n= 99, 284± 3 g b.w.) and
SHR (Okamoto, SHR/NHsd strain, n= 107, 288± 2 g b.w.) on
12/12 h light/dark cycles were allowed conventional rat chow
diet (0.7% NaCl) and water ad lib until the time of the
experiment. The rats were anesthetized with pentobarbital (70–
75 mg/kg, i.p.). As previously described (Berg et al., 2010; Berg and
Jensen, 2013), mean arterial BP [MBP= (systolic BP− diastolic
BP)/3+ diastolic BP] was monitored through a catheter in the
femoral artery, flushed with 0.15 ml PBS (0.01 M Na-phosphate,
0.14 M NaCl, pH 7.4) containing 500 IU heparin/ml. CO and
HR were recorded by a flow probe on the ascending aorta.
TPR (MBP/CO) was calculated. The rats were on a positive-
pressure ventilator throughout the experiment, ventilated with
air. Previous measurements of blood gas parameters demon-
strated adequate ventilation in both strains (Berg, 2002, 2003).
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Positive-pressure ventilation reduces right atrium ejection, and
consequently lowered CO and MBP. This reduction was significant
in SHR, but did not appear to influence the stimulated adren-
ergic responses, as previously discussed (Berg and Jensen, 2013).
Body temperature was maintained at 37–38 °C by external heating,
guided by a thermo sensor, inserted inguinally into the abdominal
cavity.
EXPERIMENTAL DESIGN
Control rats were pre-treated with PBS and infused for 15 min with
tyramine to induce NET-mediated norepinephrine release. Since
subtype-selective α2AR-agonists, which do not cross the blood-
brain barrier, are not available, I used α2AR-agonists with different
subtype profiles and different ability to cross the blood-brain
barrier. Rats were therefore pre-treated with PBS or the α2AR-
antagonist L-659,066, followed 10 min later by α2AR-agonist, i.e.,
fadolmidine, ST-91, or (R)-(+)-m-nitrobiphenyline oxalate. Rats
were also pre-treated with the AT1R-antagonist losartan, alone
or followed by L-659,066, clonidine, or ST-91. Drug specificity
and dose are given in Table 1. Blood for the measurement of
catecholamines was collected from the arterial catheter after the
15-min tyramine-observation period, but without discontinuing
the infusion.
MEASUREMENT OF PLASMA CATECHOLAMINES
About 1.5 ml blood was collected into tubes containing 40µl 0.2 M
glutathione and 0.2 M EGTA (4 °C). Plasma was stored at−80 °C
until the norepinephrine and epinephrine concentrations were
determined, using 400µl plasma and the 5000 Reagent kit for
HPLC analysis of Catecholamines in plasma from Chromsystems
GmbH, Munich, Germany, as described by the manufacturer.
DRUGS
Pentobarbital was from the Norwegian National Hospital, Oslo,
Norway. L-659,066 was a kind gift from Merck, Sharp, and Dohme
Labs, Rahway, NJ, USA, and fadolmidine HCl from Orion Cor-
poration, Espoo, Finland. ST-91 was from TOCRIS bioscience,
Bristol, UK; and (R)-(+)-m-nitrobiphenyline oxalate from Santa
Cruz Biotechnology, Heidelberg, Germany. The remaining drugs
were from Sigma Chemical Co., St. Louis, MO, USA.
STATISTICAL ANALYSES
Results are presented as mean values± SEM. Changes in the car-
diovascular parameters were expressed in % of baseline. Data were
averaged every min in all experiments. For the narrow peak-
pressor response to ST-91 and m-nitrobiphenyline, data were
averaged every 5 s. The cardiovascular response-curves to agonists
and tyramine were analyzed using Repeated Measures Analyses of
Variance and Covariance, first as over-all tests within each strain,
and subsequently for each group separately or between groups.
Significant responses and groups differences were subsequently
located using one- and two-sample Student’s t -tests, respectively,
at specific times. The plasma catecholamine concentrations, the
cardiovascular baselines, and the effect of pre-treatment were
first analyzed using one-way ANOVA, and group differences were
subsequently located by two-sample Student’s t -tests or, in the
presence of out-liers, non-parametric Kruskal–Wallis tests. For
all analyses, testing proceeded only when significant responses,
differences and/or interactions were indicated. The P-value was
for all tests and each step adjusted according to Bonferroni,
except for the catecholamine data, where P ≤ 0.05 was considered
significant.
RESULTS
α2AR- AND AT1R-INFLUENCE ON THE PLASMA CATECHOLAMINE
CONCENTRATIONS
Norepinephrine
Similar to that previously described (Berg and Jensen, 2013), the
non-selective α2AR-antagonist L-659,066 increased the tyramine-
induced norepinephrine overflow to plasma in WKY (P = 0.015)
(Table 2). A similar increase was not seen in SHR, where
the plasma norepinephrine concentration was already elevated
(P < 0.001, WKY compared to SHR controls). Pre-treatment
Table 1 | Mode of action and dose of the pharmacological agents used.
Drug Mode of action Crosses blood-brain
barrier
Dose per kg
Tyramine Norepinephrine efflux through NET No 1.26µmol/min (Berg et al., 2010)
Clonidine α2AR-agonist (non-selective) Yes 151 nmol (Berg et al., 2012; Berg
and Jensen, 2013)
Fadolmidine (Lehtimaki et al.,
2008)
α2C>B>AAR-agonist (+α1AR-agonist
activity)
No 2 nmola
ST-91 (Takano et al., 1992) α2AR-agonist (non-α2A) No 24 nmola
m-nitrobiphenyline (Crassous
et al., 2007)
α2AR-agonist (α2C-selective)
(+α2A+BAR-antagonist activity)
Not known 12.4 nmola
L-659,066 (Clineschmidt et al.,
1988)
α2AR-antagonist (non-selective) No 4.4µmol (Berg et al., 2012; Berg
and Jensen, 2013)
Losartan AT1R-antagonist Yes (Li et al., 1993) 79µmol (Berg, 2002)
aConcentration established in preliminary tests to give a substantial (50–100%) but sub-maximal increase in MBP. Tyramine was administered as a 15-min infusion,
whereas the other drugs were administered as bolus injections (0.6–1.0 ml/kg) 10 min before tyramine, except clonidine, which was injected 15 min before. All drugs
were dissolved in PBS, and administered through a catheter in the femoral vein. When pre-treatment consisted of two drugs, these were given 10 min apart.
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Table 2 |The plasma concentration of norepinephrine and epinephrine at the end of the tyramine-infusion period.
WKY SHR
N Norepinephrine
(nM)
Epinephrine
(nM)
N Norepinephrine
(nM)
Epinephrine
(nM)
PBS+ tyramine 17 20.6±0.7 2.0±0.9 16 27.4±1.8* 5.0±0.6*
L-659,066(non-selective)+PBS+ tyramine 6 26.3±2.0† 7.0±1.7† 7 30.3±3.4 10.6±2.7
PBS+ fadolmidine (α2C>B>A)+ tyramine 6 18.1±1.3 7.4±1.3† 6 23.9±2.2 13.0±2.2†
L-659,066+ fadolmidine+ tyramine 5 26.6±0.4†‡ 12.8±1.1†‡ 6 70.1±16.9†‡§ 74.8±20.7†‡§
PBS+ST-91(α2non-A)+ tyramine 6 26.5±2.9† 5.5±1.8† 8 24.0±1.8 11.0±4.1
L-659,066+ST-91+ tyramine 6 25.4±2.1† 12.7±4.2† 7 58.3±5.2†‡§ 49.3±8.0†‡§
PBS+m-nitrobiphenyline (α2C)+ tyramine 5 24.1±1.7 4.6±1.5 7 27.9±2.2 8.5±1.6
L-659,066+m-nitrobiphenyline+ tyramine 5 24.3±2.0 15.8±4.2† 7 50.1±6.0†‡§ 45.5±15.0†‡§
Losartan+ tyramine 9 18.4±0.7 4.2±1.5 6 28.4±3.4 11.8±4.1
Losartan+L-659,066+ tyramine 7 26.3±1.9†|| 25.9±10.4†|| 7 71.3±10.1†||§ 41.2±9.3†||§
Losartan+ clonidine+ tyramine 7 17.7±1.1† 1.1±0.4† 6 19.7±1.1†|| 1.6±0.8†||
Losartan+ST-91+ tyramine Not done 7 27.4±1.5 15.2±4.4
Differences were detected as indicated between corresponding SHR and WKY control groups (*), between the PBS+ tyramine controls and corresponding experi-
mental groups (†), between groups pre-treated with agonist alone (fadolmidine, ST-91, or m-nitrobiphenyline) and L-659,066+ the same agonist (‡), between groups
pre-treated with losartan alone and losartan+ L-659,066/clonidine/ST-91 (||), and between groups pre-treated with L-659,066 alone and L-659,066 combined with
agonist or losartan (§). N, number of rats per group. *, †, ‡, ||, § - P≤0.05.
with α2AR-agonist alone, i.e., fadolmidine (α2C>B>A), ST-91
(α2(non-A)), or m-nitrobiphenyline (α2C) had no effect on over-
flow in either strain, except for an increase after ST-91 in WKY.
After L-659,066+ agonist+ tyramine, norepinephrine overflow
was not different from that after L-659,066+ tyramine in WKY
(P =NS), but was much higher in SHR (P ≤ 0.025–0.004), also
when compared to the SHR PBS+ tyramine or corresponding
PBS+ agonist+ tyramine groups (P ≤ 0.004).
Losartan alone had no effect on the tyramine-induced norepi-
nephrine overflow in either strain (P =NS compared to the con-
trols). Losartan also did not influence the augmenting effect of L-
659,066 in WKY (P =NS compared to the L-659,066+ tyramine
group, and P = 0.001 compared to the WKY PBS+ tyramine
and losartan+ tyramine groups). However, in SHR, losartan
allowed L-659,066 to greatly increase norepinephrine over-
flow (P ≤ 0.005 compared to PBS/L-659,066/losartan+ tyramine
groups). Pre-treatment with losartan+ clonidine reduced the
tyramine-induced norepinephrine overflow in SHR (P ≤ 0.048
compared to the PBS/losartan+ tyramine groups), and was lower
than that in the controls, although not different from that in
the losartan+ tyramine group, in WKY. Norepinephrine overflow
after pre-treatment with losartan+ ST-91 was not different from
that in the PBS+ tyramine or losartan+ tyramine groups (tested
in SHR only).
Epinephrine
The effect of α2AR-agonists and antagonist on the surgery-
activated epinephrine secretion mostly paralleled their effect
on the tyramine-induced norepinephrine overflow in both
strains. However, pre-treatment with fadolmidine in both strains,
and L-659,066+m-nitrobiphenyline in WKY, increased cir-
culating epinephrine without altering the concentration of
norepinephrine.
THE CARDIOVASCULAR RESPONSES
The α2AR- and AT1R-influence on the cardiovascular baselines
L-659,066 reduced baseline MBP and TPR in both strains
(Table 3). All α2AR-agonists induced a transient rise in MBP and
TPR (Figure 2, the response to clonidine was similar to that previ-
ously published, Berg et al., 2012). Pre-treatment with L-659,066
reduced these TPR-responses, except that of fadolmidine in SHR
(Figure 2A), although the MBP-responses were not necessarily
reduced. Only fadolmidine subsequently induced an L-659,066-
sensitive reduction in MBP and TPR to below baseline in both
strains, and also HR in SHR. The agonists had otherwise little
effect on baseline HR. Losartan reduced baseline MBP in both
strains, HR in WKY, and TPR in SHR (Table 3). Losartan+ L-
659,066 induced a significant reduction in both HR and TPR
in both strains. Losartan increased the MBP-response to ST-91
(Figure 2B) and also the transient rise in CO and MBP in response
to clonidine in SHR but had no effect on the HR- or TPR-response
to clonidine in either strain (not shown).
The α2AR- and AT1R-influence on the cardiovascular response to
tyramine
As previously documented (Berg et al., 2010; Berg and Jensen,
2013), tyramine induced an immediate, but transient rise in TPR
(Figure 3) and a sustained increase in MBP, HR, and CO. The
present results focused on the effect of pre-treatment on the TPR-
response to tyramine, and the concomitant changes in MBP, HR,
and CO (all expressed in % of baselines) are therefore shortly
described but not shown.
Pre-treatment with α2AR-agonist alone (Figures 3A–C), i.e.,
fadolmidine, ST-91, or m-nitrobiphenyline, had no effect on
the TPR-response to tyramine in WKY (P =NS). In SHR,
the TPR-response to tyramine was increased after fadolmidine
(P = 0.023 at 15 min), not influenced by ST-91, and decreased
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Table 3 | Cardiovascular baselines prior to tyramine and, in parenthesis, the response to pre-treatment.
Pre-treatment WKY SHR
N MBP
(mm Hg)
HR
(beats/min)
CO
(ml/min)
TPR
(mmHg/ml/min)
N MBP
(mm Hg)
HR
(beats/min)
CO
(ml/min)
TPR
(mmHg/ml/min)
PBS (pooled data) 27 69±3 340±5 32±1 2.2±0.1 26 94±4* 381±6* 19±1* 5.2±0.2*
(−1±2) (−5±3) (2±0) (−0.3±0.1) (−3±5) (−17±4) (1±1) (−0.4±0.2)
L-659,066+PBS 6 62±9† 338±13 33±2 1.8±0.2 7 68±6† 408±8 18±2 3.9±0.4†
(−16±2)† (−17±9) (1±1) (−0.6±0.1)† (−21±4) (−8±9) (−1±1) (−1.1±0.2)
PBS+ fadolmidine 6 70±3 346±7 35±3 2.1±0.2 7 73±7† 352±10† 18±1 4.1±0.2†
(−13±5) (−12±6) (4±0) (−0.8±0.2) (−27±5)† (−60±10)† (1±1) (−1.8±0.2)†
L-659,066+ 5 50±2† 333±11 33±2 1.5±0.1† 6 65±7 401±10 18±1 3.7±0.4
fadolmidine (−23±3)† (−18±9) (3±1) (−0.9±0.2)† (−36±10)† (−17±13) (0±1) (−1.9±0.4)†
PBS+ST-91 6 82±5 349±4 33±5 2.8±0.5 8 82±4 378±13 14±1 6.1±0.6
(−6±2) (−30±6) (5±1) (−0.7±0.0)† (−14±6) (−35±9) (0±1) (−1.2±0.4)
L-659,066+ST-91 6 67±6 345±7 33±2 2.0±0.1 7 79±10 412±14 15±2 6.4±1.
(−4±5) (−10±9) (8±2) (−0.9±0.2)† (−26±7) (−22±8) (0±1) (−1.±0.4)
PBS+ 5 85±1 390±25 31±3 2.±0.2 7 137±8 386±6 18±1 7.5±0.5†
m-nitrobiphenyline (−9±5) (−4±11) (2±1) (−0.5±0.2) (39±8) (−10±6) (1±2) (1.8±0.8)
L-659,066+ 7 59±2 349±10 30±4 1.9±0.2 7 115±8 420±8 20±1 5.8±0.5
m-nitrobiphenyline (−11±3) (−12±6) (1±2) (−0.5±0.1) (19±7) (8±7) (1±1) (0.8±0.4)
Losartan 9 53±3 341±12 31±2 1.8±0.1 6 72±5† 376±7 13±1† 5.5±0.3
(−22±4)† (−25±5)† (0±2) (−0.7±0.2) (−24±8)† (−19±6) (−3±1) (−1.0±1.0)†
Losartan+L-659,066 9 38±3†‡ 310±7† 22±2†‡ 1.8±0.1 7 41±3†‡ 348±17† 10±2† 5.2±1.0
(−23±2)† (−44±8)† (−2±1) (−0.9±0.2)† (−48±8)† (−73±9)†‡ (−6±2)† (−0.6±0.8)
Clonidine 7 65±3 314±7 40±3 1.6±0.1† 6 60±4† 320±11† 18±1 3.4±0.2†
(−4±6) (−33±8) (11±1)† (−0.8±0.2)† (−35±10)† (−121±19)† (2±1) (−2.5±0.6)†
Losartan+ clonidine 6 54±3 346±7 35±3 1.5±0.1† 6 44±3†‡ 314±8†‡ 13±3 4.2±1.0
(−22±7) (−34±13) (10±2)†‡ (−1.4±0.2)†‡ (−65±9)†‡ (−134±12)†‡ (−2±2) (−2.9±1.3)†
Losartan+ST-91 Not done 7 54±4†‡ 358±11 13±1† 4.7±0.6
(−50±7)† (−69±8)†‡ (−5±1)† (−1.5±0.3)
Cardiovascular baselines in the PBS-control groups are shown as pooled data from experiments run at different times. However, statistical evaluation of the effect of pre-
treatment was done using control rats from the same set of experiments. Comparisons were made between theWKY and SHR controls (*), between the PBS-controls
and the experimental groups (†), between the groups pre-treated with PBS+ agonist (fadolmidine, ST-91, or nitrobiphenyline) and corresponding groups given L-
659,066+ the same antagonist (significant differences not detected), and between the groups pre-treated with losartan alone and losartan+L-659,066/clonidine/ST-91
(‡).*P≤0.0125, †, ‡ P≤Bonferroni adjusted P-value for each set of experiment.
after m-nitrobiphenyline (P = 0.003 at 3 min). L-659,066 alone
(Figure 3A) virtually eliminated the TPR-response in WKY
(P ≤ 0.008), with no additional effect when combined with ago-
nist (Figures 3A–C). In SHR, L-659,066 alone did not change
the tyramine-induced rise in TPR, but abolished the response
when combined with ST-91 (Figures 3A,B). The response to tyra-
mine in L-659,066+ fadolmidine-pre-treated SHR was less than
that after fadolmidine alone, although not different from that
in the controls (Figure 3A). Moreover, ∆TPR was not further
reduced after L-659,066+m-nitrobiphenyline compared to that
after m-nitrobiphenyline alone in SHR (Figure 3C).
A reduced MBP-response to tyramine after L-659,066,
alone or combined with agonist (fadolmidine, ST-91, or
m-nitrobiphenyline), was observed in WKY, but only after
L-659,066+ agonist in SHR. m-Nitrobiphenyline alone reduced
∆MBP in both strains. The agonists had little effect on
the tyramine-induced tachycardia, except fadolmidine which
increased ∆HR in SHR. A lower tyramine-induced rise in CO
was observed after fadolmidine and ST-91 in WKY, after fadolmi-
dine in SHR, and in all groups given L-659,066 as part of the
pre-treatment.
Losartan alone had no effect on the TPR-peak response to tyra-
mine in either strain, but induced a vasodilatory TPR-response
at the end of the tyramine-infusion in WKY (Figure 4). Like L-
659,066 alone (Figure 3A), losartan+ L-659,066 eliminated the
TPR-peak response to tyramine in WKY (Figure 4), and in addi-
tion caused a fall in TPR to below baseline. Losartan+ clonidine,
like clonidine alone, had no effect on the TPR-response to tyra-
mine in WKY (Figure 4). In SHR, losartan+ L-659,066 and losar-
tan+ clonidine, unlike losartan, L-659,066 or clonidine alone,
eliminated the TPR-response to tyramine. The TPR-peak response
was reduced also after pre-treatment with losartan+ ST-91 (tested
in SHR only, Figure 4). Losartan did not alter the MBP-response
to tyramine, but increased the CO-response in both strains. This
increase was eliminated when losartan was combined with L-
659,066, and in WKY also with clonidine. The tyramine-induced
www.frontiersin.org June 2013 | Volume 4 | Article 70 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Berg Failing catecholamine release-control in hypertension
FIGURE 2 |The MBP-,TPR-, HR-, and CO-response to α2AR-agonists.
Fadolmidine (α2C>B>AAR) (A), ST-91 [α2(non-A)AR] (B), and m-nitrobiphenyline
(α2CAR, with additional α2A+BAR-antagonistic activity) (C) were injected alone
or after pre-treatment with the non-selective α2AR-antagonist L-659,066. The
response-curves were analyzed using Repeated Measures Analyses of
Variance and Covariance (please see Materials and Methods for details).
Significant responses (*within symbols) and group differences (*in brackets)
were located as indicated at peak response (all agonists) (brackets left of
curves) and after 15 min (fadolmidine only) (brackets right of curves).
*, *P ≤0.025 for (A), and ≤0.05 for (B,C) after curve evaluations.
tachycardia was increased in SHR after losartan+ clonidine,
similar to that seen after clonidine alone.
DISCUSSION
The main finding in the present study was that the failing α2AAR
inhibition of peripheral norepinephrine and epinephrine release
in SHR during tyramine-stimulated norepinephrine release was
restored by stimulation of the α2CAR or inhibition of the AT1R.
α2CAR-stimulation and AT1R-inhibition also restored the failing
postsynaptic α2AR control of vascular tension in SHR.
As previously described (Berg and Jensen, 2013), α2AR-
mediated auto-inhibition of peripheral catecholamine release
was demonstrated in tyramine-stimulated WKY by an increased
norepinephrine overflow to plasma after pre-treatment with
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FIGURE 3 |TheTPR-response to tyramine-induced norepinephrine
release after pre-treatment with α2(non-A)AR-selective agonist, alone
or combined with L-659,066. The peripherally restricted
α2C>B>AAR-agonist fadolmidine (A), the peripherally restricted
α2(non-A)AR-selective agonist ST-91 (B), and the α2C-selective agonist
m-nitrobiphenyline with additional α2A+BAR-antagonistic activity (C) were
injected alone or after pre-treatment with the peripherally restricted
α2AR-antagonist L-659,066. Baselines prior to tyramine are shown in
Table 3. Significant responses (*within symbol) and differences
between the control and experimental groups were located at peak
response (*brackets left of curves) and at 15 min (*brackets right of
curves). *, *P ≤0.025 after curve evaluations.
FIGURE 4 |TheTPR-response to tyramine after pre-treatment with the
AT1R-antagonist losartan, alone or combined with L-659,066, clonidine,
or ST-91. The effect of losartan+ST-91 was tested in SHR only. Baselines
prior to tyramine are shown inTable 3. Significant responses (*within
symbol) and group differences were detected at peak response (*brackets
left of curves) and at 15 min (*brackets right of curves) as indicated. *,
*P ≤0.025 after curve evaluations.
the non-selective α2AR-antagonist L-659,066. This increase was
eliminated after addition of the non-selective α2AR-agonist cloni-
dine (Berg and Jensen, 2013), but not, as demonstrated by the
present experiment, by agonists with less or no α2AAR reactiv-
ity, such as fadolmidine, ST-91, or m-nitrobiphenyline. Clonidine
reduced the tyramine-induced norepinephrine overflow in SHR,
and this reduction was fully reversed by L-659,066 (Berg and
Jensen, 2013), and, again, a similar decrease was not seen after
fadolmidine, ST-91, or m-nitrobiphenyline. Both tyramine and
L-659,066 are peripherally restricted, i.e., do not pass the blood-
brain barrier (Oldendorf, 1971; Clineschmidt et al., 1988). Inhi-
bition of tyramine-stimulated norepinephrine overflow therefore
involved in both strains peripherally located α2AR, predominantly
of the α2A-subtype, in agreement with that previously observed by
others (Starke, 2001; Brede et al., 2004).
Epinephrine is secreted directly into blood and not subjected to
local re-uptake, and release is therefore not stimulated by tyramine
(Berg and Jensen, 2013). However, the stress induced by the sur-
gical procedure activated some secretion of epinephrine from the
adrenals (Berg et al., 2012). Clonidine precipitated an L-659,066-
sensitive reduction in this secretion in both strains (Berg et al.,
2012; Berg and Jensen, 2013), whereas fadolmidine, ST-91, or m-
nitrobiphenyline did not. It therefore appeared that the α2AAR
inhibited also the secretion of epinephrine, in agreement with
previous studies on the rat adrenal gland (Lymperopoulos et al.,
2007). This differed from that in the mouse, where theα2C-subtype
inhibited epinephrine secretion (Brede et al., 2003; Moura et al.,
2006).
Although clonidine reduced tyramine-induced norepinephrine
overflow to plasma in SHR, the antagonist L-659,066 failed to
increase overflow in this strain (Berg and Jensen, 2013). This
malfunction depended on the tyramine-stimulated release of
norepinephrine, since L-659,066, and also the α2AR-antagonist
yohimbine, clearly increased norepinephrine overflow in SHR
not stimulated with tyramine but where NET-re-up-take was
blocked by desipramine (Berg et al., 2012). However, norepineph-
rine overflow was greatly increased in tyramine-stimulated SHR
when L-659,066 was combined with the α2CAR-reactive agonist
fadolmidine, which has a 35 and 10 times higher affinity for the
α2C- and α2BAR than the rat α2A-subtype, respectively (Lehtimaki
et al., 2008). Overflow was also greatly increased when L-659,066
was combined with the non-A-selective ST-91 (Takano et al.,
1992), or the α2CAR-selective m-nitrobiphenyline, which in addi-
tion has an α2A+BAR-antagonistic effect (Crassous et al., 2007).
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Since fadolmidine and ST-91 do not cross the blood-brain barrier
(Clineschmidt et al., 1988; Lehtimaki et al., 2008), stimulation of
peripheral α2CAR appeared to re-establish α2A-auto-inhibition in
SHR (Figure 1).
Augmented tyramine-induced norepinephrine overflow was
also observed in SHR but not in WKY after pre-treatment with
losartan+ L-659,066, whereas losartan alone had no effect. G-
protein Gq-signaling agents, including angiotensin II through
the AT1R, have been shown in isolated mouse atria to stimulate
norepinephrine release by interfering with down-stream signal-
ing of the inhibitory α2AR-Gi pathway (Figure 1) (Cox et al.,
2000; Trendelenburg et al., 2003a). The AT1R interaction involved
only the α2C- and not the α2A-subtype (Cox et al., 2000; Tren-
delenburg et al., 2003a). α2CAR-agonist may therefore restore
α2A-auto-inhibition by counter-acting the AT1R-Gq-interference,
and losartan by eliminating the AT1R-interference. Thus, as could
be expected, ST-91 did not alter the tyramine-induced norepi-
nephrine overflow after losartan in SHR. The present results were
therefore compatible with studies showing that the reduced affer-
ent renal nerve signaling observed in response to efferent renal
sympathetic nerve activation was increased in SHR by the α2AR-
antagonist rauwolscine, and further potentiated when rauwolscine
was combined with losartan, whereas losartan alone had no effect
(Kopp et al., 2011).
However, the experimental approach is indirect and performed
in the whole animal, and other explanations should therefore also
be considered. For instance, α2CAR-stimulation will hamper renal
renin release (Michel and Rump, 1996), and, through that, may
lower AT1R-activation and stimulation of release. However, if this
was the mechanism responsible, one might have expected losar-
tan alone to lower the release of norepinephrine, which it did not.
Unlike vesicular release, NET-mediated release has been consid-
ered not to be regulated by presynaptic receptors (Starke, 2001).
However, recent studies show that NET may indeed be influenced
by presynaptic control, as demonstrated by the hampering effect of
muscarinic receptor activation on the NET transport rate (Parker
et al., 2010), a response which in other cells is mediated through
a PKC-dependent pathway (Apparsundaram et al., 1998). How-
ever, PKC did not seem to influence tyramine-induced transport
through NET, since preliminary studies showed that the PKC-
inhibitor staurosporine, like losartan alone, did alter norepineph-
rine overflow (plasma norepinephrine concentration= 19.8± 2.3
and 27.1± 2.3 nM in WKY and SHR, respectively, five rats/group,
P =NS compared to the controls, Berg, unpublished observa-
tions). α2AR-agonists have also been shown to bind to NET and to
competitively inhibit re-uptake of a norepinephrine analog (Park
et al., 2013). This response was not prevented by α2AR-antagonist,
and was therefore likely to result from their structural similarity to
norepinephrine and not from α2AR-signaling. Agonist inhibition
of NET did not seem to alter the tyramine-induced reversed trans-
port of norepinephrine through NET, since none of the present
agonists lowered tyramine-induced overflow, and the reduction
observed in SHR after clonidine was abolished by L-659,066 (Berg
and Jensen, 2013).
The secretion of epinephrine mostly followed the same pat-
tern as that of norepinephrine overflow, indicating that α2AAR
failed to inhibit also epinephrine secretion in SHR, and that
this malfunction could be restored by α2CAR-stimulation or
AT1R-inhibition.
The tyramine-stimulated norepinephrine overflow after L-
659,066+ agonist and losartan+ L-659,066 was about two times
greater, and that of epinephrine 10 times greater, than that in the
control or L-659,066-only groups in SHR, but not higher than
that after pre-treatment with L-659,066 alone in WKY, i.e., 28%
higher than in the controls. L-659,066 and yohimbine greatly
increased the plasma concentration of norepinephrine and epi-
nephrine also in desipramine-treated, non-stimulated SHR (Berg
et al., 2012). These observations suggested an up-regulation of
peripheral, presynaptic α2AAR in SHR, in order to down-regulate
the elevated sympathetic tone and/or to compensate for the failing
α2AR-auto-inhibition in this strain.
L-659,066 reduced baseline MBP and TPR in both strains, but
abolished the tyramine-induced rise in TPR in WKY only. Also
the Gi-inhibitor pertussis toxin eliminated the TPR-response to
tyramine in this strain alone (Berg et al., 2009). The abolished
TPR-response was most likely due to that L-659,066 inhib-
ited postsynaptic, VSMC α2AR-Gi-signaling, thereby allowing
VSMC βAR-adenylyl cyclase-mediated dilatation to oppose the
norepinephrine-induced, α1AR-mediated vasoconstriction. Also
this α2AR-function failed in SHR. The malfunction appeared to
be precipitated by the stimulated release of norepinephrine, since
a strain-related difference was not seen in the moderating effect of
L-659,066 on the TPR-response to exogenous α1AR-agonist (Berg
et al., 2012). Like the failing control of catecholamine release,
also this disorder was repaired by AT1R-inhibition or α2CAR-
stimulation, since losartan+ L-659,066 and L-659,066+ ST-91
eliminated the TPR-response to tyramine. This may be due to
the high norepinephrine and/or epinephrine release in these SHR
groups, which, in the presence of the α2AR-antagonist inhibiting
VSMC α2AR, may be sufficient to re-establish a βAR-mediated
counter-action of the norepinephrine-induced α1AR-mediated
vasoconstriction. This conclusion is in agreement with our pre-
vious study showing that neuronally activated, β1AR-mediated
vasodilatation counter-acted the TPR-response to tyramine in
WKY only, whereas β2+3AR activated by epinephrine from the
adrenals opposed the late half of the TPR-response in SHR (Berg
et al., 2010). The TPR-response to tyramine in SHR was also elim-
inated after losartan+ clonidine and reduced after losartan+ ST-
91, in spite of a normal plasma norepinephrine concentration.
It is therefore possible that also the failing β1AR contribution to
TPR-control in SHR resulted from VSMC AT1R-activation.
In agreement with studies on genetically modified mice, where
the initial clonidine-induced vasoconstriction was due to activa-
tion of VSMC α2BAR (Link et al., 1996), the present agonists,
and as previously described also clonidine (Berg et al., 2012),
induced a transient rise in TPR, which was reduced or eliminated
by L-659,066, except that of fadolmidine in SHR. The L-659,066-
sensitive fraction of this vasoconstriction may be mediated
through the α2BAR on VSMC, although the present experiments
could not exclude a role of the α2AAR. However, the L-659,066-
sensitive fraction of the response to m-nitrobiphenyline was likely
to be mediated through VSMC α2CAR, since this α2C-selective
agonist also acted as an α2A+BAR-antagonist (Crassous et al.,
2007). Although VSMC α2CAR did not contribute to BP control
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in genetically modified mice (MacDonald et al., 1997), stimulated
α2CAR-mediated vasoconstriction has been demonstrated in veins
and arterioles (Chotani et al., 2004; Görnemann et al., 2007). The
L-659,066-insensitive part of the agonist-induced vasoconstric-
tion was likely to be mediated throughα1AR, since at least fadolmi-
dine contained α1AR-agonistic activity (Lehtimaki et al., 2008).
The latter component may also explain why fadolmidine increased
the TPR-response to tyramine in SHR. This increase was absent
after additional pre-treatment with L-659,066, possibly due to that
L-659,066, by inhibiting the VSMC α2AR-Gi pathway, allowed
norepinephrine-stimulated, βAR-mediated vasodilatation, in that
manner opposing the tyramine-induced, α1AR-mediated vaso-
constriction. Fadolmidine was the only agonist which induced
a late L-659,066-sensitive fall in MBP, TPR, and HR in SHR,
possibly due to its α2AAR-component, which may lower cate-
cholamine release prior to tyramine-stimulation and/or stimulate
endothelial, vasodilatory α2AAR (Shafaroudi et al., 2005). The
TPR-response to tyramine was reduced by m-nitrobiphenyline.
This reduction was not further influenced by additional pre-
treatment with L-659,066, and was therefore likely to result from
theα2A+BAR-antagonistic effect of this agonist. The TPR-response
was therefore more sensitive to the promiscuity of the α2AR-
agonists than theα2AR-mediated control of catecholamine release.
CONCLUSION
Peripheral α2AR represent the last line of defense against adren-
ergic hyperactivity. The α2A-subtype played a dominating role in
limiting peripheral catecholamine release in WKY, but failed to do
so in SHR. This malfunction was restored after α2CAR-stimulation
or AT1R-inhibition, suggesting that an AT1R-Gq/α2CAR-Gi-
interaction disturbed normal α2AAR-mediated control of cat-
echolamine release in SHR. This α2CAR-AT1R-interaction may
be responsible for the elevated plasma norepinephrine concen-
trations observed in SHR, and contribute to the sympathetic
hyperactivity and hypertension in this strain. A loss-of-function
α2CAR deletion polymorphism has been shown to be more fre-
quent in African–Americans and connected to a greater HR-
and BP-response in the cold-pressor-test (Kurnik et al., 2008).
An augmented sympathetic response to this stress-test is linked
to increased cardiovascular morbidity (Matthews et al., 2004),
and heart failure patients with the same α2CAR polymorphism
had a worsened prognosis and increased risk of heart fail-
ure (Small et al., 2002, 2003). Estrogen stimulated the expres-
sion of α2CAR in human dermal arteriole VSMC (Eid et al.,
2007), and may from the present results provide a mecha-
nism whereby estrogen protects against hypertension. A failing
α2AAR auto-inhibition of catecholamine release due to an AT1R-
α2CAR interaction may therefore be highly relevant for develop-
ment of hypertension, the major risk factor for cardiovascular
events.
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